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Background. The parotid gland is an unusual site for metastatic disease and when metastasis occurs, it commonly originates from
head and neck primaries. Spread from distant infraclavicular sites such as the breast, into the parotid, is even more unusual with
very few cases reported in the literature.Case Report.We describe the case of a 65-year-old woman presenting for a rapidly enlarging
right parotidmass. She had a history of an invasive ductal carcinoma of the right breast and was disease-free in the past 6 years prior
to her presentation. She was thereafter diagnosed as having a solitary parotid metastasis from breast origin. A total parotidectomy
was done and she was referred for adjuvant radiotherapy. Conclusion. Any parotid metastasis should be investigated, especially in
patients with a prior history of cancer where the possibility of metastasis, even if improbable, should be kept in mind. Fine needle
aspiration biopsy (FNAB) is the first diagnostic procedure to be done and immunocytochemistry can provide valuable information
even if it is not always needed for diagnosis. Superficial parotidectomy when feasible with adjuvant radiotherapy is the preferred
approach for solitary metastasis of the parotid. The prognosis, however, remains poor regardless of the treatment modality used.
1. Introduction
Malignant neoplasms of the salivary glands are uncom-
mon constituting approximately 3–5% of all head and neck
malignancies and 0.5–1% of all cancers [1]. The incidence
of malignant salivary gland tumors is estimated at 1.3 cases
per 100000 per year [2] accounting for about 12% of cases
of cancer of the oral cavity and pharynx [2], the latter
representing 3.5% of all cancers inmen and 1.5% of all cancers
inwomen [3]. Primarymalignancies of the salivary glands are
by far the most frequent, and although metastatic disease to
the salivary glands represents less than 10% of salivary gland
tumors [1], it should be considered on the list of differentials.
The rich lymphoid content of the salivary glands makes
an ideal ground for seeding of head and neck primaries.
Malignancies from distant infraclavicular sites also spread
to the salivary glands, usually to the submandibular glands
and to a lesser extent the parotids. The spread is most likely
hematogenous [4]. Although rarely encountered, metastatic
disease to the salivary glands is widely reported in themedical
literature as isolated case reports or small series. In the
parotids, metastases from breast, kidney, and lung primaries
are the most frequently reported ones. We are describing
herein the case of a postmenopausal patient who presented
with a cheek mass associated with a partial peripheral facial
nerve palsy, caused by a parotid gland metastasis from breast
origin, with a review of the literature.
2. Case Report
A 65-year-old lady from Syrian descent was referred to our
institution in September 2014 for painless rapidly enlarging
mass of the right cheek, which she noted only for 2 months
prior to presentation. Relevant history included an early stage
right breast invasive ductal carcinoma diagnosed 6 years
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Figure 1: Pet CT showing accumulation of 18-FDG in the right
parotid gland.
earlier and treated by a lumpectomy with ipsilateral axillary
lymph nodes dissection, followed by 6 cycles of adjuvant
chemotherapy with CMF (cyclophosphamide, methotrexate,
and 5-fluorouracil), focal radiotherapy to the chest wall and
right axilla, and subsequent hormonal manipulation with
letrozole for 5 years.
The patient was disease-free for the following 6 years until
a growing right cheek mass led her to seek medical advice.
Physical exam revealed a palpable firm, nontender, non-
mobile right inferior parotid mass of 2 cm at the level of the
angle of themandible.The right corner of themouth dropped
with asymmetry that increased with facial expression, thus
indicating right mandibular branch palsy. The rest of the
exam did not reveal any palpable cervical, supraclavicular, or
axillary lymph nodes on both sides. Fibroscopy was done and
was normal.
Contrast enhanced MRI scan of the neck revealed the
presence of a 2 cm ill-defined mass of the right parotid gland
at the inferior border, hypointense on T1 and mild hyperin-
tense on T2 with moderate enhancement after gadolinium
injection. No cervical lymphadenopathy was detected. Fine
needle aspiration biopsy (FNAB) of the parotidmass revealed
the presence ofmalignant cells of breast origin. Staging FDG-
PET CT scan was obtained showing accumulation of 18-FDG
in the right parotid and ruled out other distant or locoregional
metastases (Figure 1).
A total parotidectomy was subsequently done with
preservation of all facial nerve branches. However, the
dissection of the mandibular branch was done with prob-
able remnant of tumor cells on the nerve. The retroau-
ricular vein was sacrificed because of direct invasion by
the tumor. The anatomic pathology report confirmed the
secondary nature of the tumor (of breast origin) invading
the parotid parenchyma with perineural and perivascular
invasion (Figure 2). Although immunocytochemistry was
not done on the FNA sample and was not needed for
diagnosis, immunostaining with anti-estrogen receptor (ER)
antibodies was performed on the final surgical pathology
Figure 2: Parotid: H&E ×40: neoplastic ducts (right upper part of
the image) invading the parotid parenchyma (left lower part of the
image).
Figure 3: Parotid: immunostain with anti-estrogen receptors anti-
body ×40: the nuclei of the malignant cell are highlighted in brown.
Parotid ducts are seen in the lower part of the image.
specimen and further supported the diagnosis as the tumoral
cells were ER positive (Figure 3). GATA3 immunostaining, a
specific marker for breast cancer, was also done confirming
the breast origin of the tumor (Figure 4).
The patient tolerated well the procedure and was referred
for adjuvant radiotherapy.
3. Discussion
Parotid metastasis of breast origin is an extremely rare event,
and only few cases are reported in the literature.
The parotid glands are the largest major salivary glands
and are the only salivary glands to contain intraglandular
lymph nodes; the submandibular and sublingual glands do
not. The parotid lymph nodes are divided into 2 layers: a
superficial nodal layer located between the gland and its
capsule and a deep layer located within and beneath the gland
[5]. These lymph nodes drain the frontal and lateral aspects
of the scalp, lateral aspects of the lids, conjunctiva, external
auditory canal, root of the nose, the lacrimal gland, and the
parotid itself.
Metastatic disease involving the parotid accounts for
approximately 9 to 14% of all parotid tumors [6]. Head and
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Figure 4: GATA3 nuclear expression in neoplastic cells (GATA3
immunostaining ×200) confirming the breast origin of the parotid
tumor.
neck tumors make up to two-thirds of these metastases,
squamous cell carcinoma and malignant melanomas from
the upper airway and the foregut being the most common,
followed by the skin [7]. However, metastases from distal
primaries such as the breast, GI tract, kidneys, and prostate
are quite rare and thought to reach the parotids through the
thoracic duct or Batson’s paraspinal venous plexus, skipping
the pulmonary filter [8].
The submandibular glands can also be involved with
metastatic spread. However, due to lack of any lymphatic
network draining the skin and subcutaneous tissue of the
head and neck, 85% of such metastasis arises from infra-
clavicular primary tumors, most commonly breast, kidney,
and small cell lung carcinomas [9]. Squamous cell carcinoma
of the head and neck is unlikely to metastasize into the
submandibular gland andwhen it does so, the primary tumor
is usually in the ipsilateral oral cavity in close proximity to the
gland or it has spread into an adjacent level I cervical lymph
node [10]. Therefore, metastasis to the submandibular gland
from head and neck primaries occurs primarily by direct
contiguous invasion, whereas those originating from distant
infraclavicular sites spread via the hematogenous route. To
our knowledge, metastatic tumors have not been described
in sublingual or accessory salivary glands.
Very few cases have been described in which the parotid
was the only or major site of metastasis [11]. Parotid
metastases are also reported synchronously with the initial
presentation of the patient and metachronous years after
the primary diagnosis [12] as in our case, after 6 years of
being disease-free. Metastases below the clavicle are mostly
from renal, lung, and breast carcinoma [13]. Less commonly,
metastases from primary tumors of the gastrointestinal or
genitourinary tracts into the parotid are reported. And anec-
dotal cases such as a primary urachal adenocarcinoma of the
bladder [14], gastric adenocarcinoma [13], and hepatocellular
carcinoma [15] were reported.
The majority of parotid metastasis from breast origin
reported in literature is of invasive ductal carcinoma [6].
However, metastases from invasive lobular carcinoma and
even malignant phyllodes tumor were described. Cases of
involvement of the contralateral parotid are equally reported
as the ipsilateral one which further supports the likely
hematogenous route for tumoral spread versus direct lym-
phatic invasion [4].
Most patients with a parotid neoplasm present with a
painless mass or swelling of the gland. Signs or symptoms
of facial nerve involvement are suggestive of a malignant
origin rather than a benign tumor. Up to 30–40% of patients
with parotid malignancies present with peripheral facial
nerve paralysis [12]. Radiological workup with computed
tomography and MRI is used to further support the clinical
assessment regarding the benign or malignant nature of the
tumor and to define its location (intra- versus extraglandular)
and extent and detect any nodal or distant spread. However,
one cannot distinguish a primary malignant tumor of the
parotid from a metastasis based on imaging criteria [16].
Fine needle aspiration (FNA) has an important role in the
workup of a parotid mass as it can assist the surgeon in treat-
ment planning in case of malignant involvement. FNA has
an 85% accuracy in distinguishing between malignant and
benign lesions of the parotid and can differentiate primary
neoplasms of the parotid frommetastatic disease [17]. Rarely,
FNA results may be misleading such as a case of parotid
metastasis from hepatocellular carcinoma reported by Yu
et al. where FNA did not show any specific cytopathologic
features to allow an appropriate diagnosis.
Regarding spread from breast origin, FNA can pose a
diagnostic challenge for the cytologist, as primary salivary
duct carcinoma and metastatic ductal carcinoma from the
breast share many morphological and immunocytochemical
characteristics. This emphasizes the importance of com-
municating the clinical history to the pathologist as pri-
mary salivary duct carcinoma mainly affects elderly males
and its association with ductal carcinoma of the breast
(metachronous or synchronous tumor) is unlikely and rarely
described in the literature [6]. When metastatic carcinoma is
identified on parotid FNA, restaging with FDG-PET CT scan
is recommended to evaluate locoregional and look for distant
disease. Treatment is planned according to radiological stag-
ing.
When cytopathology result fits with the clinical history,
it is sufficient to make an appropriate diagnosis as reflected
in our case. Metastatic ductal carcinoma to the parotid has
an infiltrating aspect, often showing residual normal parotid
acini between the neoplastic glands. In contrast, salivary
ductal carcinoma is infiltrative but also expansile, leaving no
or very rare normal parotid gland elements between its neo-
plastic cells. Moreover, metastatic breast ductal carcinoma
lacks the aspect of intraductal cribriform carcinoma that is
characteristic of primitive salivary ductal carcinoma of the
parotid gland [18]. Immunocytostaining adds little benefit
as primary and metastatic ductal carcinoma of the parotid
share similar immunocytochemical features; however, the
absence of expression of estroprogestinic receptors favors
the diagnosis of a primary ductal tumor of the parotid
gland [18]. In addition, salivary ductal carcinoma has been
reported to express almost invariably androgen receptors
[19]. Comparing the hormone receptors immunoprofile of
both the parotid tumor and the primary breast tumor can
be helpful although phenotypic discrepancies regarding the
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expression of hormone receptors between primary tumor and
metastasis have been described in up to 25% of cases [7].
The management of a sole parotid metastasis of breast
origin is still controversial. Nevertheless, an appropriate
parotidectomy with negative margins and with preservation
of the facial nerve when possible is preferred. Superficial
parotidectomy was successful in providing local control in
most cases [12]. In our case, the deep lobe of the parotid was
involved and total parotidectomy inevitable. Some authors
suggested ipsilateral neck dissection [8, 16]; however, only
limited data exists regarding the benefit of such procedure,
such cases being very rare. Shi et al. advocate the use of an
ipsilateral neck dissection when the metastasis is from head
and neck primaries as spread occurred predominantly via
the lymphatic system, whereas, in cases of hematogenous
spread from distant sites, neck dissection is thought to
be unnecessary. Adjuvant radiotherapy to the parotid and
neck is recommended by most authors for patients without
nodal involvement; however, others favor the use of adjuvant
chemotherapy, the rationale behind it being the possible
coexistence of occult and microscopic metastasis, reserving
the use of irradiation for cases where local control could not
be achieved by surgery alone [7].
Although metachronous solitary parotid metastases with
longer disease-free survival are considered as good prognos-
tic factors [16], many authors consider that parotid surgery
does not improve life expectancy [14], and themanagement of
a parotid metastasis is palliative regardless of the therapeutic
modality used as the prognosis of such patients is dismal
with a 5-year survival rate of only 10% [6]. Our patient
underwent a total parotidectomy with preservation of the
facial nerve; however, we believe microscopic tumor was
left behind around the nerve, and the patient was therefore
offered postoperative focal radiotherapy.
4. Conclusion
A parotid mass in a patient with a prior history of a malig-
nancy should be investigated and considered as metastasis
from the primary disease until proven otherwise. The possi-
bility of coexisting primary neoplasm of the parotid, benign
or malignant, should also be investigated and ruled out. FNA
is the first step and will guide further diagnostic workup.
Immunocytochemistry can provide additional information
when histopathologic features are not diagnostic. Superficial
parotidectomy and adjuvant radiotherapy are the preferred
approach when the parotid is the only site of recurrence.
There are no guidelines in this regard and the reported 5-year
survival is 10%; treatment is therefore considered by many as
palliative.
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